


Claims

1. Use of a combination of:

(a) a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^1 is -L-(5-6 membered heteroaryl) or -L-(phenyl), where said 5-6 membered heteroaryl or phenyl is optionally substituted by one to three R^3 ;

R^2 is $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_7$ cycloalkyl, where said $\text{C}_3\text{-C}_7$ cycloalkyl is optionally substituted by $\text{C}_1\text{-C}_4$ alkyl;

L is a bond or methylene; and

each R^3 is independently $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy or $\text{SO}_2\text{-C}_1\text{-C}_4$ alkyl, where each $\text{C}_1\text{-C}_4$ alkyl is optionally substituted by F, OH or $\text{C}_1\text{-C}_4$ alkoxy; and

(b) a compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

R^4 is H, F, or Cl;

R^5 is H, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_5$ fluoroalkyl or $\text{C}_3\text{-C}_8$ cycloalkyl, where each said $\text{C}_1\text{-C}_5$ alkyl and $\text{C}_1\text{-C}_5$ fluoroalkyl is optionally substituted by R^8 and each said $\text{C}_3\text{-C}_8$ cycloalkyl is optionally substituted by R^9 ;

R⁶ is H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R⁸;

R⁷ is H, F or Cl;

each R⁸ is independently OH, C₁-C₄ alkoxy or NR¹⁰R¹¹;

each R⁹ is independently F, C₁-C₄ alkyl, C₁-C₄ alkoxy, or NR¹⁰R¹¹; and

each R¹⁰ and R¹¹ is independently H or C₁-C₂ alkyl;

in the manufacture of a medicament for treating cancer.

2. The use of claim 1, wherein the compounds of (a) and (b), or a pharmaceutically acceptable salt or solvate thereof, are to be administered with: (c) an additional anti-cancer agent.

3. The use of claim 1 or 2, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, bladder cancer, colon cancer, uterine cancer, prostate cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.


4. The use of claim 2 or 3, wherein the cancer is hormone receptor positive (HR+) breast cancer and the additional anti-cancer agent is an endocrine therapeutic agent selected from the group consisting of an aromatase inhibitor, a selective estrogen receptor modulator (SERM) and a selective estrogen receptor degrader (SERD).

5. The use of claim 4, wherein the endocrine therapeutic agent is letrozole or fulvestrant.

6. The use of any one of claims 1 to 5, wherein the compound of Formula (I) is (1*R*,3*S*)-3-[3-({[3-(methoxymethyl)-1-methyl-1*H*-pyrazol-5-yl]carbonyl}amino)-1*H*-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate (PF-07104091) monohydrate.

7. The use of claim 6, wherein the amount of PF-07104091 is from about 75 mg to about 500 mg BID.

8. The use of claim 7, wherein the amount of PF-07104091 is about 75 mg BID, about 150 mg BID, or about 225 mg BID.
9. The use of any one of claims 1 to 8, wherein the compound of Formula (II) is a hydrate of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (PF-07220060).
10. The use of claim 9, wherein the amount of PF-07220060 is from about 100 mg to about 500 mg BID.
11. The use of claim 10, wherein the amount of PF-07220060 is about 100 mg BID, about 200 mg BID, or about 300 mg BID.
12. The use of any one of claims 1 to 11, wherein the cancer is a palbociclib resistant cancer.
13. The use of any one of claims 1 to 11, wherein the subject has previously been treated with a CDK4/6 inhibitor.
14. The use of claim 13, wherein the CDK4/6 inhibitor is palbociclib.
15. A combination comprising:
(a) a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:


R¹ is -L-(5-6 membered heteroaryl) or -L-(phenyl), where said 5-6 membered heteroaryl or phenyl is optionally substituted by one to three R³;

R² is C₁-C₆ alkyl or C₃-C₇ cycloalkyl, where said C₃-C₇ cycloalkyl is optionally substituted by C₁-C₄ alkyl;

L is a bond or methylene; and

each R³ is independently C₁-C₄ alkyl, C₁-C₄ alkoxy or SO₂-C₁-C₄ alkyl, where each C₁-C₄ alkyl is optionally substituted by F, OH or C₁-C₄ alkoxy; and

(b) a compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

R⁴ is H, F, or Cl;

R⁵ is H, C₁-C₅ alkyl, C₁-C₅ fluoroalkyl or C₃-C₈ cycloalkyl, where each said C₁-C₅ alkyl and C₁-C₅ fluoroalkyl is optionally substituted by R⁸ and each said C₃-C₈ cycloalkyl is optionally substituted by R⁹;

R⁶ is H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R⁸;

R⁷ is H, F or Cl;

each R⁸ is independently OH, C₁-C₄ alkoxy or NR¹⁰R¹¹;

each R⁹ is independently F, C₁-C₄ alkyl, C₁-C₄ alkoxy, or NR¹⁰R¹¹; and

each R¹⁰ and R¹¹ is independently H or C₁-C₂ alkyl;

wherein the combination of (a) and (b) is effective in treating cancer.

16. The combination of claim 15, further comprising (c) an additional anti-cancer agent; wherein the combination of (a), (b) and (c) is effective in treating cancer.

17. The combination of claim 15 or 16, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, bladder cancer, colon cancer, uterine cancer, prostate cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.

18. The combination of claim 16 or 17, wherein the cancer is hormone receptor positive (HR+) breast cancer and the additional anti-cancer agent is an endocrine therapeutic agent selected from the group consisting of an aromatase inhibitor, a selective estrogen receptor modulator (SERM) and a selective estrogen receptor degrader (SERD).

19. The combination of claim 18, wherein the endocrine therapeutic agent is letrozole or fulvestrant.

20. The combination of any one of claims 15 to 19, wherein the compound of Formula (I) is (1*R*,3*S*)-3-[3-({[3-(methoxymethyl)-1-methyl-1*H*-pyrazol-5-yl]carbonyl}amino)-1*H*-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate (PF-07104091) monohydrate.

21. The combination of claim 20, wherein the amount of PF-07104091 is from about 50 mg to about 250 mg BID.

22. The combination of claim 21, wherein the amount of PF-07104091 is about 75 mg BID, about 150 mg BID, or about 225 mg BID.


23. The combination of any one of claims 15 to 22, wherein the compound of Formula (II) is a hydrate of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (PF-07220060).

24. The combination of claim 23, wherein the amount of PF-07220060 is from about 100 mg to about 500 mg BID.

25. The combination of claim 24, wherein the amount of PF-07220060 is about 100 mg BID, about 200 mg BID, or about 300 mg BID.

26. A combination comprising:

(a) a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^1 is -L-(5-6 membered heteroaryl) or -L-(phenyl), where said 5-6 membered heteroaryl or phenyl is optionally substituted by one to three R^3 ;

R^2 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl, where said C_3 - C_7 cycloalkyl is optionally substituted by C_1 - C_4 alkyl;

L is a bond or methylene; and

each R^3 is independently C_1 - C_4 alkyl, C_1 - C_4 alkoxy or SO_2 - C_1 - C_4 alkyl, where each C_1 - C_4 alkyl is optionally substituted by F, OH or C_1 - C_4 alkoxy; and

(b) a compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

R^4 is H, F, or Cl;

R⁵ is H, C₁-C₅ alkyl, C₁-C₅ fluoroalkyl or C₃-C₈ cycloalkyl, where each said C₁-C₅ alkyl and C₁-C₅ fluoroalkyl is optionally substituted by R⁸ and each said C₃-C₈ cycloalkyl is optionally substituted by R⁹;

R⁶ is H, C₁-C₄ alkyl or C₁-C₄ fluoroalkyl, where each said C₁-C₄ alkyl and C₁-C₄ fluoroalkyl is optionally substituted by R⁸;

R⁷ is H, F or Cl;

each R⁸ is independently OH, C₁-C₄ alkoxy or NR¹⁰R¹¹;

each R⁹ is independently F, C₁-C₄ alkyl, C₁-C₄ alkoxy, or NR¹⁰R¹¹; and

each R¹⁰ and R¹¹ is independently H or C₁-C₂ alkyl,

for use in therapy.